Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Harry Ahdieh"'
Publikováno v:
Journal of Opioid Management. 6:181-191
Objective: To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain. Design: Post hoc analysis of two ≥1-year open-label extension studies. Setting: Multiple US canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7c9fc81347f8d16f204da2beea4ce25
https://doi.org/10.5055/jom.2010.0016
https://doi.org/10.5055/jom.2010.0016
Publikováno v:
Clinical Therapeutics. 29:1000-1012
Patients are typically switched from parenteral opioids to oral opioids during the 24 to 48 hours after surgery. In June 2006, an oral immediate-release (IR) tablet formulation of oxymorphone was approved for the treatment of acute moderate to severe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afcb0ba681dab9abe19a686a968f5137
https://doi.org/10.1016/j.clinthera.2007.06.001
https://doi.org/10.1016/j.clinthera.2007.06.001
Publikováno v:
The Journal of Pain. 8:175-184
Opioid-experienced (N = 250) patients with chronic, moderate to severe low back pain (LBP) were converted from their prestudy opioid(s) to an approximately equianalgesic dose of OPANA ER (oxymorphone extended release). Patients continued slow titrati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d177128452b9d20dc2e5bab83313f865
https://doi.org/10.1016/j.jpain.2006.09.011
https://doi.org/10.1016/j.jpain.2006.09.011
Autor:
Roland Gerritsen van der Hoop, Nathaniel P. Katz, Richard Rauck, Rosemary Kerwin, Harry Ahdieh, Gilbert Podolsky, Tina Ma
Publikováno v:
Current Medical Research and Opinion. 23:117-128
Determine the efficacy and tolerability of oxymorphone extended release (OPANA ER) in opioid-naive patients with moderate to severe chronic low back pain (CLBP).Patientsor = 18 years of age were titrated with oxymorphone ER (5- to 10-mg increments ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af2c3c087a22b694ade0624ff9f81e50
https://doi.org/10.1185/030079906x162692
https://doi.org/10.1185/030079906x162692
Publikováno v:
Pain Medicine. 6:357-366
Objective. To compare oxymorphone extended release (ER) and placebo on indices of pain, function, and safety in patients with chronic osteoarthritis (OA) pain. Design. In this multicenter, double-blind, placebo- and active-controlled, parallel-group,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e5230210bca1abc9fe626bbcf0ed36d
https://doi.org/10.1111/j.1526-4637.2005.00057.x
https://doi.org/10.1111/j.1526-4637.2005.00057.x
Autor:
Harris McIlwain, Harry Ahdieh
Publikováno v:
American Journal of Therapeutics. 12:106-112
A 52-week, multicenter, open-label extension study was performed to evaluate the safety, tolerability, and effectiveness of oxymorphone extended release (ER), a novel tablet formulation of oxymorphone hydrochloride, in 153 patients with moderate to s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b4c42352c78b7245580c024681d943b
https://doi.org/10.1097/01.mjt.0000139442.65914.f9
https://doi.org/10.1097/01.mjt.0000139442.65914.f9
Publikováno v:
Current Medical Research and Opinion. 20:911-918
To compare the analgesic efficacy and safety of oxymorphone extended release (ER) and oxycodone controlled release (CR) in patients with moderate to severe cancer pain.This randomized, multicenter, double-blind, 2-period crossover study included adul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79442e1edf4d071fef59a636a7e4e81e
https://doi.org/10.1185/030079904125003854
https://doi.org/10.1185/030079904125003854
Autor:
Harry Ahdieh, Michael P. Adams
Publikováno v:
Pharmacotherapy. 24:468-476
Study Objective. To evaluate the pharmacokinetics and dose-proportionality of four dose strengths (5, 10, 20, and 40 mg) of oxymorphone extended release (ER) under both single-dose and steady-state conditions. Design. Randomized, three-period, four-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b6a6948d7f600b9763638cb903e027
https://doi.org/10.1592/phco.24.5.468.33347
https://doi.org/10.1592/phco.24.5.468.33347
Autor:
Nathaniel P. Katz, Penney Cowan, Harry Ahdieh, Richard Malamut, Carl L. Roland, Deborah B. Leiderman, Pamela Palmer, Richard C. Dart, John S. Brownstein, Michael Klein, Edward Michna, Richard A. Denisco, Sarah Peirce-Sandner, Roger D. Weiss, Laurie B. Burke, Alec B. O'Connor, Edgar H. Adams, Srinivasa N. Raja, Sandra D. Comer, Kerry Wolf, Christine Rauschkolb, Dennis C. Turk, James P. Zacny, Petra Jacobs, Robert H. Dworkin, Lynn R. Webster, John D. Markman, Amina Chaudhry, Bob A. Rappaport, Jennifer Sharpe Potter, Robert Lubran, Nabarun Dasgupta
Opioids are essential to the management of pain in many patients, but they also are associated with potential risks for abuse, overdose, and diversion. A number of efforts have been devoted to the development of abuse-deterrent formulations of opioid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af7f5619dc66052df6ca7aa6751637dc
Publikováno v:
Pain medicine (Malden, Mass.). 9(7)
Assess the effectiveness and tolerability of a program of gradual dose titration with oxymorphone extended release (ER) for treatment of moderate to severe chronic pain in opioid-naive patients.Open-label, nonrandomized 6-month study with a titration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::816f22120e30cc5ad36d654cdbbc0484
https://pubmed.ncbi.nlm.nih.gov/18950436
https://pubmed.ncbi.nlm.nih.gov/18950436